Shares of Tiziana Life Sciences rose after the company said it received positive results from its nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury. The stock was up 5.3% to 84 cents ...
In a new study, scientists at the Leibniz Institute for Neurobiology (LIN) and University Hospital Magdeburg demonstrated that the spinal cord is far more than just a transmission pathway that ...
Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...
Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...
Spinal cord stimulation can be an effective treatment for managing pain associated with diabetic peripheral neuropathy, especially if other therapies have been ineffective. Following a trial period, ...
Spinal cord injury (SCI) is characterized by the temporary or permanent loss of motion or sensation function caused by damage to the spinal cord. Among the mechanisms behind SCI, neuroinflammation is ...